2024-11-13 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**1. Performance vs. S&P 500 (VOO)**

AbbVie Inc. (ABBV) is a research-based biopharmaceutical company developing and marketing a broad range of medicines. ABBV has outperformed the S&P 500 (VOO) with a cumulative return of 213.82% compared to VOO's 179.55%. This represents a 34.27% outperformance, placing it in the 46.29th percentile of historical outperformance relative to VOO. 

Here is a table summarizing the performance metrics of ABBV compared to VOO:

| Metric | ABBV | VOO |
|---|---|---|
| Cumulative Return | 213.82% | 179.55% |
| Outperformance | 34.27% | - |
| Relative Outperformance Percentile | 46.29% | - |

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|---|---|---|---|---|---|
| 2015-2017 | 63.2% | 29.6% | 24.8% | 1.0 | 170.9 |
| 2016-2018 | 79.0% | 32.3% | 46.7% | 1.0 | 162.9 |
| 2017-2019 | 61.4% | 40.1% | 9.7% | 1.1 | 156.5 |
| 2018-2020 | 26.1% | 40.1% | -21.2% | 0.8 | 189.3 |
| 2019-2021 | 77.3% | 33.8% | -22.7% | 0.7 | 239.3 |
| 2020-2022 | 107.4% | 33.8% | 83.8% | 0.6 | 285.6 |
| 2021-2023 | 66.5% | 21.2% | 31.6% | 0.4 | 273.9 |
| 2022-2024 | 41.9% | 21.2% | 11.4% | 0.3 | 308.2 |

The table indicates that ABBV has exhibited strong alpha and beta performance in the past, demonstrating its ability to outperform the market and provide substantial growth.

**2. Recent Price Movement:**

* Closing Price: 171.45 (Last Market: 171.49)
* 5-day Moving Average: 189.42
* 20-day Moving Average: 192.29
* 60-day Moving Average: 193.08

The current price is below the 5, 20, and 60-day moving averages, suggesting a potential downward trend. However, the recent price movement is relatively stable.

**3. Technical Indicators:**

* RSI: 35.03
* PPO: -1.18
* Recent (20-day) Relative Divergence: -30.43 (-) indicating a short-term downward trend.
* Expected Return: 29.62% 

The RSI level indicates that ABBV is currently in oversold territory, which could signal a potential rebound. The PPO is negative, implying a weakening momentum. The recent relative divergence indicates a short-term downward trend. The 29.62% expected return implies that long-term (2+ years) investment in ABBV is expected to generate a significant return compared to S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-30 | 3 | 2.92 |
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |

ABBV has consistently exceeded earnings expectations in recent quarters. In the most recent quarter (2024-10-30), ABBV reported an EPS of $3, exceeding the consensus estimate of $2.92. This strong performance indicates a healthy financial condition and a positive outlook for the company.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $14.46B | 70.87% |
| 2024-06-30 | $14.46B | 70.94% |
| 2024-03-31 | $12.31B | 66.74% |
| 2023-12-31 | $14.30B | 60.11% |
| 2023-09-30 | $13.93B | 53.44% |

ABBV exhibits a consistent trend of strong revenue growth and profitability.  The company's profit margins have been consistently high, indicating a strong competitive advantage and effective management.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $6.03B | 25.88% |
| 2024-06-30 | $6.78B | 20.21% |
| 2024-03-31 | $8.01B | 17.10% |
| 2023-12-31 | $10.36B | 7.93% |
| 2023-09-30 | $12.09B | 14.70% |

The table shows that ABBV has a robust financial position with a healthy ROE, indicating the efficient use of shareholder equity to generate profits. 

**6. News and Recent Issues:**

* **Recent Earnings News:**  No significant news was found in the past 2 days regarding ABBV's earnings.
* **Market Outlook:**  ABBV's market outlook is positive, with analysts citing the company's strong revenue growth, profitability, and robust pipeline of new drug developments as key drivers. 
* **Analyst Opinions and Performance Highlights:**  FINBOLD reports that ABBV has a strong buy rating from most analysts. The company has demonstrated a strong track record of delivering consistently high returns, placing it among the top-performing pharmaceutical companies in the market.

**7. Overall Analysis:**

ABBV is a financially strong company with a strong track record of performance and a promising outlook. The company's robust financials, consistent revenue growth, and solid pipeline of new drugs suggest a positive future for ABBV. The recent underperformance compared to the market is likely a short-term trend and doesn't change the company's long-term potential. The oversold RSI level suggests that ABBV might be undervalued and presents a potential opportunity for long-term investors. The company's high expected return compared to S&P 500 further strengthens the investment case.

**Conclusion:**

Based on its strong performance, robust financials, and positive outlook, ABBV presents a compelling investment opportunity for long-term investors seeking exposure to the pharmaceutical sector. The company's consistent outperformance compared to the market, coupled with its strong growth potential, positions ABBV as a valuable addition to any diversified portfolio.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. You should always consult with a financial professional before making any investment decisions. 
